Chugai Pharmaceutical (OTCMKTS:CHGCY) Hits New 12-Month Low – What’s Next?

Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY) shares hit a new 52-week low during mid-day trading on Thursday . The company traded as low as $20.08 and last traded at $21.37, with a volume of 1439 shares trading hands. The stock had previously closed at $21.05.

Analyst Ratings Changes

CHGCY has been the topic of several recent analyst reports. UBS Group lowered shares of Chugai Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 6th. Nomura upgraded shares of Chugai Pharmaceutical to a “hold” rating in a report on Tuesday, September 1st. Zacks Research raised shares of Chugai Pharmaceutical to a “hold” rating in a research report on Friday, May 29th. Finally, The Goldman Sachs Group upgraded shares of Chugai Pharmaceutical from a “hold” rating to a “buy” rating in a research note on Monday, June 15th. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy”.

Chugai Pharmaceutical Trading Up 1.2%

The stock has a market cap of $68.30 billion, a PE ratio of 22.55 and a beta of 0.59. The business has a 50 day moving average of $21.88 and a 200-day moving average of $24.81.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last posted its quarterly earnings data on Friday, July 24th. The company reported $0.22 earnings per share for the quarter. The business had revenue of $2.14 billion during the quarter, compared to the consensus estimate of $2.38 billion. Chugai Pharmaceutical had a return on equity of 23.76% and a net margin of 35.09%. Research analysts expect that Chugai Pharmaceutical Co., Ltd. Unsponsored ADR will post 0.96 EPS for the current fiscal year.

Chugai Pharmaceutical Company Profile

Chugai Pharmaceutical Co, Ltd. is a Japan-based research-driven pharmaceutical company headquartered in Tokyo. Founded in 1925, the company focuses on discovering, developing, manufacturing and commercializing prescription medicines, with an emphasis on biotechnology and innovative therapies for serious and unmet medical needs.

Chugai’s principal therapeutic areas include oncology, hematology, immunology, neuroscience and renal diseases. Its products include Actemra (known as RoActemra in some markets) for inflammatory and immune-related conditions, Hemlibra for hemophilia A, and Alecensa for certain forms of lung cancer.